The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study
2014; Oxford University Press; Volume: 36; Issue: 6 Linguagem: Inglês
10.1093/eurheartj/ehu272
ISSN1522-9645
AutoresA. C. Morton, Alexander Rothman, John P. Greenwood, Julian Gunn, Alexander Chase, Bernard Clarke, Alistair S. Hall, Keith A.A. Fox, Claire Foley, Winston Banya, Duolao Wang, Marcus Flather, David C. Crossman,
Tópico(s)Acute Myocardial Infarction Research
ResumoAimsAcute coronary syndromes (ACSs) are driven by inflammation within coronary plaque. Interleukin-1 (IL-1) has an established role in atherogenesis and the vessel-response to injury. ACS patients have raised serum markers of inflammation. We hypothesized that if IL-1 is a driving influence of inflammation in non-ST elevation ACS (NSTE-ACS), IL-1 inhibition would reduce the inflammatory response at the time of ACS.
Referência(s)